The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and children aged 9 years and older.

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...